Skip to main content
. 2016 Feb 13;7(12):14458–14475. doi: 10.18632/oncotarget.7363

Figure 4. Inhibition of WIP1 potentiates the checkpoint through activation of the p53 pathway.

Figure 4

A. MCF7 cells were pulsed with BrdU, treated with DMSO or GSK2830371 (0.5 μM) and exposed to IR. Cells were incubated in the presence of nocodazole and collected after 20 h. Fraction of BrdU positive cells that progressed to mitosis (pH3 marker) was determined by flow cytometry. Error bars represent SD. B. MCF7 cells were treated as in A. Fraction of BrdU negative cells with 2n DNA content (corresponding to G1) was determined by flow cytometry 20 h after treatment. Error bars represent SD. C, D. MCF7 cells were treated with DMSO or GSK2830371 (0.5 μM), exposed to IR and BrdU incorporation (C) or cell cycle profile (D) was determined after 3 days. Error bars represent SD. E. MCF7 cells were treated with DMSO or GSK2830371 (0.5 μM), exposed to IR and cell proliferation was analyzed after 6 days. Error bars represent SD. F. MCF7 cells were treated as in E and cell proliferation was determined by colony formation assay after 6 days. Representative image from three independent experiments is shown.